Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday

Key Points

• Legend Biotech is expected to report Q2 2026 results before the market opens on August 11. Analysts forecast earnings of approximately $0.06 per share and revenue of about $356 million.
• In the prior quarter, the company reported a $0.03-per-share loss, missing estimates, while revenue rose 56.5% year over year to $305.1 million.
• LEGN shares recently traded near $19.10, well below their 52-week high of $39.16. Analysts maintain a “Moderate Buy” consensus, with an average price target of $55.29.

Legend Biotech (NASDAQ:LEGN - Get Free Report) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of $0.0563 per share and revenue of $355.9630 million for the quarter. Investors may visit the the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). Legend Biotech had a negative return on equity of 24.92% and a negative net margin of 21.98%.The business had revenue of $305.10 million during the quarter, compared to the consensus estimate of $306.51 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The company's revenue was up 56.5% compared to the same quarter last year. On average, analysts expect Legend Biotech to post $-0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Legend Biotech Stock Performance

Shares of LEGN stock traded up $0.09 on Tuesday, hitting $19.10. 1,175,605 shares of the company's stock traded hands, compared to its average volume of 2,497,735. Legend Biotech has a one year low of $16.24 and a one year high of $39.16. The company's fifty day simple moving average is $27.77 and its 200 day simple moving average is $23.24. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of -28.12 and a beta of 0.37.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LEGN. Weiss Ratings raised shares of Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday. JPMorgan Chase & Co. began coverage on Legend Biotech in a research note on Monday, July 13th. They set a "neutral" rating and a $35.00 price objective on the stock. Morgan Stanley decreased their price objective on Legend Biotech from $49.00 to $48.00 and set an "overweight" rating on the stock in a report on Wednesday, May 13th. Benchmark reissued a "buy" rating on shares of Legend Biotech in a research note on Tuesday, July 28th. Finally, TD Cowen increased their target price on Legend Biotech to $29.00 and gave the company a "hold" rating in a report on Wednesday, May 13th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $55.29.

Insider Buying and Selling

In related news, CEO Ying Huang sold 5,566 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the sale, the chief executive officer directly owned 241,872 shares in the company, valued at $3,574,868.16. This represents a 2.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.02% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Legend Biotech

A number of large investors have recently added to or reduced their stakes in the company. First Trust Advisors LP purchased a new stake in shares of Legend Biotech during the second quarter worth about $411,000. Squarepoint Ops LLC raised its position in Legend Biotech by 77.6% during the 2nd quarter. Squarepoint Ops LLC now owns 148,681 shares of the company's stock valued at $5,277,000 after purchasing an additional 64,956 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Legend Biotech by 16.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 84,081 shares of the company's stock valued at $2,984,000 after purchasing an additional 11,771 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Legend Biotech by 3.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,560,596 shares of the company's stock worth $55,386,000 after buying an additional 52,344 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in Legend Biotech in the 2nd quarter worth approximately $15,790,000. Institutional investors own 70.89% of the company's stock.

Legend Biotech Company Profile

Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.